Hormonal Treatment of Fibrocystic Disease

[1]  P. Bruzzi,et al.  Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast , 1997, BMJ.

[2]  L. Brinton,et al.  Breast cancer risk associated with proliferative breast disease and atypical hyperplasia , 1993, Cancer.

[3]  I. Fentiman,et al.  Recent developments in the study of benign breast disease. , 1993 .

[4]  B. J. Harrison,et al.  Plasma fatty acid profiles in benign breast disorders , 1992, The British journal of surgery.

[5]  I. Forsyth,et al.  The mammary gland. , 1991, Bailliere's clinical endocrinology and metabolism.

[6]  J. Hoskinson,et al.  AETIOLOGY AND TREATMENT , 1991 .

[7]  I. Fentiman,et al.  LHRH analogue for treatment of recurrent and refractory mastalgia. , 1990, Annals of the Royal College of Surgeons of England.

[8]  R. Mansel,et al.  European multicentre trial of bromocriptine in cyclical mastalgia , 1990, The Lancet.

[9]  H. Leis.  Management of nipple discharge , 1989, World Journal of Surgery.

[10]  M. Baum.  Benign breast disease: The cost of the service and the cost to the patient , 1989, World journal of surgery.

[11]  R. Blamey,et al.  Long-term follow up of patients treated with a single course of danazol for recurrent breast cysts. , 1989, British journal of clinical practice. Supplement.

[12]  R. Mansel,et al.  Management of breast pain and nodularity , 1989, World journal of surgery.

[13]  B. J. Harrison,et al.  Low-dose danazol for mastalgia. , 1989, British journal of clinical practice. Supplement.

[14]  B. J. Harrison,et al.  Non‐cyclical mastalgia: An improved classification and treatment , 1989, The British journal of surgery.

[15]  F. Peters,et al.  Hyperprolactinemia and nonpuerperal mastitis (duct ectasia). , 1989, JAMA.

[16]  I. Fentiman,et al.  Dosage and duration of tamoxifen treatment for mastalgia: A controlled trial , 1988, The British journal of surgery.

[17]  T. Powles,et al.  TAMOXIFEN AND BENIGN BREAST PROBLEMS , 1987, The Lancet.

[18]  C. Brown,et al.  Effects of danazol on incidence of progesterone and oestrogen receptors in benign breast disease. , 1987, British medical journal.

[19]  J. Russo,et al.  Development of the Human Mammary Gland , 1987 .

[20]  M. Williams,et al.  A controlled trial of danazol in the treatment of multiple recurrent breast cysts , 1986, The British journal of clinical practice.

[21]  R. Blamey,et al.  A double-blind controlled trial of danazol and bromocriptine in the management of severe cyclical breast pain. , 1986, The British journal of clinical practice.

[22]  A. Döberl,et al.  Reduction of Cysts in Fibrocystic Breast Disease during and after Danazol Treatment , 1986 .

[23]  I. Fentiman,et al.  DOUBLE-BLIND CONTROLLED TRIAL OF TAMOXIFEN THERAPY FOR MASTALGIA , 1986, The Lancet.

[24]  H. Vorherr.  Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management. , 1986, American journal of obstetrics and gynecology.

[25]  R. Mansel,et al.  PREDICTION OF RESPONSE TO ENDOCRINE THERAPY IN PRONOUNCED CYCLICAL MASTALGIA USING DYNAMIC TESTS OF PROLACTIN RELEASE , 1985, Clinical endocrinology.

[26]  R. Mansel,et al.  CLINICAL EXPERIENCE OF DRUG TREATMENTS FOR MASTALGIA , 1985, The Lancet.

[27]  L. Dennerstein,et al.  Progesterone and the premenstrual syndrome: a double blind crossover trial. , 1985, British medical journal.

[28]  M. Dowsett,et al.  Endocrine effects of danazol in the treatment of endometriosis , 1984, British journal of obstetrics and gynaecology.

[29]  R. Greenblatt,et al.  Fibrocystic "disease" of the breast. , 1982, The New England journal of medicine.

[30]  C. Schuerch,et al.  A pathologic study of benign breast diseases in Tokyo and New York , 1982, Cancer.

[31]  S. Love,et al.  Fibrocystic Disease of the Breast — A Nondisease? , 1982 .

[32]  A. C. Wentz.  Adverse effects of danazol in pregnancy. , 1982, Annals of internal medicine.

[33]  R. Sellwood,et al.  Bromocriptine in severe cyclical breast pain , 1982, The British journal of surgery.

[34]  R. Mansel,et al.  CONTROLLED TRIAL OF THE ANTIGONADOTROPIN DANAZOL IN PAINFUL NODULAR BENIGN BREAST DISEASE , 1982, The Lancet.

[35]  P. Ylöstalo,et al.  Bromocriptine and Norethisterone in the Treatment of Premenstrual Syndrome , 1982, Obstetrics and gynecology.

[36]  H. Bohnet,et al.  Changes of prolactin secretion following long-term danazol application. , 1981, Fertility and sterility.

[37]  K J Ryan,et al.  Danazol: endocrine pharmacology and therapeutic applications. , 1981, American journal of obstetrics and gynecology.

[38]  C. Bodian,et al.  Breast Carcinoma: Risk and Detection , 1981 .

[39]  J. Buster,et al.  Bromocriptine in the Treatment of Premenstrual Tension Syndrome , 1980, Obstetrics and gynecology.

[40]  R. Greenblatt,et al.  The treatment of benign breast disease with danazol. , 1980, Fertility and sterility.

[41]  K. Menon,et al.  Evidence that danazol inhibits gonadotropin-induced ovarian steroidogenesis at a point distal to gonadotropin-receptor interaction and adenosine 3',5' cyclic monophosphate formation. , 1980, American journal of obstetrics and gynecology.

[42]  D. Calne,et al.  Bromocriptine. A clinical and pharmacological review. , 1980 .

[43]  B. Sherman,et al.  Endocrine consequences of continuous antiestrogen therapy with tamoxifen in premenopausal women. , 1979, The Journal of clinical investigation.

[44]  I. Ricciardi,et al.  Tamoxifen-induced regression of benign breast lesions. , 1979, Obstetrics and gynecology.

[45]  W. Dmowski,et al.  Endocrine properties and clinical application of danazol. , 1979, Fertility and sterility.

[46]  T. Mygind,et al.  Treatment of mastalgia with bromocriptine: a double-blind cross-over study. , 1979, British medical journal.

[47]  D. Graham,et al.  Adult pre-sacral teratoma. , 1979, Postgraduate medical journal.

[48]  Brooks Jd.  Danazol treatment of benign breast disease: a survey of U.S.A. multi-centre studies. , 1979 .

[49]  J. Day.  Clinical trials in the premenstrual syndrome , 1979 .

[50]  J. J. Graham,et al.  Prolactin Suppression in the Treatment of Premenstrual Syndrome , 1978, The Medical journal of Australia.

[51]  R. Mansel,et al.  A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease , 1978, The British journal of surgery.

[52]  R. Mansel,et al.  Mastalgia: psychoneurosis or organic disease? , 1978, British medical journal.

[53]  F. Kuttenn,et al.  Traitement des mastopathies bénignes par la progestérone et les progestatifs. Résultats en fonction du type de la mastopathie (à propos de 260 observations). , 1978 .

[54]  B. Andersch,et al.  Treatment of premenstrual tension syndrome with bromocriptine. , 1978, Acta endocrinologica. Supplementum.

[55]  P. Franchimont,et al.  The effect of danazol on anterior pituitary function. , 1977, Fertility and sterility.

[56]  J. Larsen,et al.  EFFECT OF BROMOCRIPTINE ON THE PREMENSTRUAL SYNDROME. A DOUBLE‐BLIND CLINICAL TRIAL , 1977, British journal of obstetrics and gynaecology.

[57]  I. Mowszowicz,et al.  Inadequate corpus luteal function in women with benign breast diseases. , 1977, The Journal of clinical endocrinology and metabolism.

[58]  R. Greenblatt,et al.  The use of an impeded androgen--danazol--in the management of benign breast disorders. , 1977, American journal of obstetrics and gynecology.

[59]  D. Piers.  THYROID CANCER AND THERAPY WITH 131I , 1976, The Lancet.

[60]  T. Lind,et al.  HOW DOES DANAZOL WORK? , 1976, The Lancet.

[61]  L. J. Benedek-Jaszmann,et al.  PREMENSTRUAL TENSION AND FUNCTIONAL INFERTILITY Aetiology and Treatment , 1976, The Lancet.

[62]  B. Macmahon,et al.  Oral contraceptives and reduced risk of benign breast diseases. , 1976, The New England journal of medicine.

[63]  K. Wilson,et al.  The effect of danazol in the treatment of chronic cystic mastitis. , 1976, Obstetrics and gynecology.

[64]  Jacques Lb.  Letter: Standardisation of heparin for clinical use. , 1975 .

[65]  B. Ringelhann,et al.  Letter: Pseudohyperkalaemia in acute myeloid leukaemia. , 1974, Lancet.

[66]  C. A. Paulsen,et al.  Pituitary and testicular function studies. I. Experience with a new gonadal inhibitor, 17-alpha-pregn-4-en-20-yno-(2,3-d)isoxazol-17-ol (Danazol). , 1971, The Journal of clinical endocrinology and metabolism.

[67]  R. Greenblatt,et al.  Clinical studies with an antigonadotropin-Danazol. , 1971, Fertility and sterility.